|
Hi Everyone,
What started as a slight dip in trading this morning for INOL has turned out to be massive decline. There’s no getting round the fact that INOL might have suffered from some unscrupulous trading and for that we apologize if any of you suffered as a result. The really interesting thing is that INOL started off pretty strong. After opening at 0.04, 0.018 cents above its previous close of 0.022, the play jumped to a high of 0.05. In early trading therefore, traders saw net realizable intraday gains of up to 25%. You’d have had to be very quick in capitalizing on those gains though because shortly after that the unscrupulous bunch moved in and sent INOL tumbling. Volume levels on the back of today’s decline have been exceptionally heavy, and more than 6M shares have changed hands. This has been a near 4600% increase over average volume of 131K. The whole thing has been a right whole mess and it is such a shame given the incredible gain potential inherent in INOL . The company has we’ve highlighted is one of the leading providers of in-demand DNA testing solutions. The market for these types of solutions is worth more than 26B annually, with more and more sub-markets popping up all the time. INOL ’s big slump today doesn’t take away the fact that the company is fundamentally sound and has the potential to reward traders, big time. The company’s 52-week high is 125 dollars after all, and gain potential like that doesn’t come along often. We will continue as always to monitor INOL for you and as soon as we see an opportunity for a reversal of today’s dip in ROI, we will sound the alarm. In the meantime lace up your trading boots and get ready for another potential chart-buster we’ve been working on. The fundamentals are sound and the technical setup is very inviting, so as soon as we finish the main report on it we’ll send out the alert. Once again please have our sincerest apologies for the INOL performance today. If you would like to receive our alerts before the crowd, please take 7 seconds to sign up for our Premium SMS Alerts Grab your cell phone and text the word PICKS to 86677 Cheers, THE NEW HOLEINONE TEAM |
Hi Everyone, What started as a slight dip
Top 10 Most Recent News Articles
JNJ's Dual-Antigen Therapy Shows Promise in Prostate Cancer
Exploring a New Front in Cancer Treatment Johnson & Johnson (NYSE: JNJ) just dropped a bombshell at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, unveiling data that could reshape prostate cancer care. Their pioneering combo of pasritamig and JNJ-9401, a dual-antigen-targeted therapy, has the scientific community buzzing. Yeah, it's just Phase 1 baby...
Continue Reading
Antengene’s AnTenGager-D2 Advances in Cancer Treatment
Antengene's AnTenGager-D2 Offers Fresh Hope Alright, let's dig into the latest buzz from the 2026 Society for Immunotherapy of Cancer conference about Antengene's AnTenGager-D2 platform. If you're not into biotech lingo, buckle up, because this is a ride into the future of cancer treatments—where science fiction might soon become science fact. A Novel Approach to Tumor...
Continue Reading
Allergan Aesthetics Study Shows Rising Patient Satisfaction
Enhanced Patient Satisfaction with Aesthetic Treatments Dive into the latest studies from Allergan Aesthetics—AbbVie's heavyweight in the beauty battleground. If you've got an ounce of optimism left in this market, their recent findings might just lift your spirits. Phase 4 studies, namely HARMONY IN DIVERSITY and HALO, are showing highly positive results among patients...
Continue Reading
TCL's Display Future: AI Meets Screens at DTC 2026
Exploring New Horizons in Display Technology There's something brewing in Wuhan: a conference that’s shaping up like a tech enthusiast’s dream. This year, it's all about the symbiosis of cutting-edge tech and dazzling visuals as TCL CSOT gears up to unveil advancements at the Global Display Tech-Ecosystem Conference (DTC) 2026. If you're wondering whether this event...
Continue Reading
Amplifon Data Breach Spurs Legal Scrutiny for Millions
Data Breach Fallout: Amplifon Under Fire When a big player like Amplifon gets hit with a data breach, it's like a wake-up call across the board. This one’s no small spill—over 1.3 million folks left wondering whether their personal information is fluttering around cyberspace for all who dare to peek. If you’ve missed the memo, Edelson Lechtzin LLP, the savvy cats in...
Continue Reading
Novo's Semaglutide Shows Promise in MASH Study
Semaglutide, a name on the lips of many investors looking for breakthroughs, is making waves again. This time, the stir comes from recent findings in the MASH field, and it's got folks in white coats quite excited. Revolutionary Results from Novo Novo Nordisk has announced promising results from their phase 3 ESSENCE trial that looks into semaglutide's effects on a...
Continue Reading
Innovent's SINTBILO® Hits Primary Endpoint in Study
Innovent's Latest Breakthrough with SINTBILO® One moment you're sipping coffee, the next you're staring at a clinical milestone. Innovent Biologics has shouted from the rooftops that their drug, SINTBILO® (tafolecimab injection), has wrapped up its Phase 3 CREDIT-5 study, snagging the primary endpoint with both hands. This isn't just any drug; it's marked as the first...
Continue Reading
Stavian Group Eyes AI-Driven Southeast Asia Growth
AI and Infrastructure: A New Chapter for Southeast Asia What does Southeast Asia's future look like with AI steering the ship? Well, there's a fresh breeze of change blowing, and right at the heart of it stands Stavian Group. At the recently held inaugural Fortune SEA500 Summit in Ho Chi Minh City, this conglomerate threw its hat into the ring, painting a vision of growth...
Continue Reading
FFR's OmniMind Takes Top Spot In RoboColiseum Rankings
The AI Race Heats Up with FFR's Big Win Stop the presses—FFR's OmniMind AI just snagged the top spot on RoboColiseum's global rankings. Yeah, you heard right, this ain't just some run-of-the-mill news. As of November 6, they've parked themselves in pole position, beating out heavyweights like NVIDIA's GR00T N1.7 and GPT-6 Astra. That's like hitting a grand slam right...
Continue Reading
GlycoNex Eyes Japanese Market with Denosumab Biosimilar
A Strategic Step into the Japanese Market Alright folks, there's a new kid aiming to shake things up in the biotech neighborhood, and it's GlycoNex with its denosumab biosimilar, SPD8. These guys just tossed their hat in the ring with a regulatory submission to Japan's Pharmaceuticals and Medical Devices Agency (PMDA). If the cosmic forces align, they might snag an...
Continue ReadingTop 5 Most Recently Viewed Articles
VivoPower Innovates with XRP-Focused Treasury Strategy
VivoPower's Transformational XRP Strategy VivoPower International PLC (NASDAQ: VVPR) has recently embarked on a groundbreaking journey by announcing a new strategy centered on the digital asset XRP. The company is positioning itself as the first publicly traded entity to implement an XRP-focused digital asset treasury. This innovative approach is not only exciting for...
Continue Reading
Recognizing Excellence in Product Stewardship for 2024
Celebrating Product Stewardship Excellence The Product Stewardship Society has announced a significant honor for 2024—Lynn L. Bergeson has been named the recipient of the prestigious Allan K. Fleeger Distinguished Service Award. This esteemed award has been established to acknowledge the remarkable contributions of individual product stewards who have played crucial...
Continue Reading
Gold Hits New Heights Amid Tensions and Election Uncertainty
Gold Prices Surge to Record Heights In recent trading, gold prices have reached unprecedented levels, reflecting a significant rise driven by various factors, including political uncertainties and ongoing international conflicts. As anticipation surrounding a highly competitive U.S. presidential election grows, along with persistent tensions in regions such as the Middle...
Continue Reading
Paul Jebely Joins Sterlington as Aviation Law Vice Chair
Paul Jebely Joins Sterlington as New Partner Sterlington PLLC is excited to announce that Paul Jebely has joined the firm as their new Partner and Vice Chair of International, marking a crucial advancement in their aviation law practice. Jebely is not just any attorney; he is a globally recognized authority in private aviation law, especially known for his work with...
Continue Reading
William James Wartinbee III Executes Significant Sell Strategy
William James Wartinbee III Implements Key Sell Strategy In a noteworthy insider sale, William James Wartinbee III, the Executive Vice President at Gartner (IT), has sold 210 shares of the company. This transaction was documented in a Form 4 filing with the U.S. Securities and Exchange Commission, and the sale was valued at about $103,275. Examining Gartner's Current...
Continue Reading